CD40 配体的 T 细胞非依赖性抗肿瘤作用。
T-cell-independent antitumor effects of CD40 ligation.
机构信息
Department of Human Oncology and Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
出版信息
Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337.
Abstract
CD40 ligation has been shown to induce antitumor effects in mice and cancer patients. Most of the studies have focused on the ability of an agonistic anti-CD40 mAb to either directly kill CD40-positive tumor cells or activate T-cell immune responses. In this review the authors focus on the ability of CD40 ligation to activate antitumor effector mechanisms of the cells of innate immunity such as macrophages and NK cells.
摘要
CD40 交联已被证明可在小鼠和癌症患者中诱导抗肿瘤作用。大多数研究都集中在激动性抗 CD40 mAb 直接杀死 CD40 阳性肿瘤细胞或激活 T 细胞免疫反应的能力上。在这篇综述中，作者重点介绍了 CD40 交联激活先天免疫细胞（如巨噬细胞和 NK 细胞）抗肿瘤效应机制的能力。
相似文献
1
T-cell-independent antitumor effects of CD40 ligation.CD40 配体的 T 细胞非依赖性抗肿瘤作用。
Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337.
2
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.先天性和适应性免疫治疗方法在小鼠黑色素瘤模型中的有效联合
J Immunol. 2017 Feb 15;198(4):1575-1584. doi: 10.4049/jimmunol.1601255. Epub 2017 Jan 6.
3
In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.体内CD40连接可诱导涉及巨噬细胞的非T细胞依赖性抗肿瘤效应。
J Leukoc Biol. 2006 Jun;79(6):1181-92. doi: 10.1189/jlb.0405191. Epub 2006 Mar 24.
4
CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.CD40连接通过一种依赖干扰素-γ的机制激活小鼠巨噬细胞，从而在体外导致肿瘤细胞破坏。
J Immunol. 2005 May 15;174(10):6013-22. doi: 10.4049/jimmunol.174.10.6013.
5
Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.环磷酰胺联合抗 CD40 mAb 和 CpG 在小鼠中增强 T 细胞非依赖性抗肿瘤作用。
J Immunother. 2011 Jan;34(1):76-84. doi: 10.1097/CJI.0b013e318200b28a.
6
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.抗CD40单克隆抗体治疗后T细胞对淋巴瘤的免疫反应。
J Immunol. 2002 Mar 15;168(6):2720-8. doi: 10.4049/jimmunol.168.6.2720.
7
CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.体内CD40连接即使对免疫原性肿瘤也可诱导不依赖T细胞的抗肿瘤效应。
Cancer Immunol Immunother. 2008 Aug;57(8):1151-60. doi: 10.1007/s00262-007-0447-4. Epub 2008 Jan 24.
8
Agonistic CD40 antibodies and cancer therapy.激动性 CD40 抗体与癌症疗法。
Clin Cancer Res. 2013 Mar 1;19(5):1035-43. doi: 10.1158/1078-0432.CCR-12-2064.
9
Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.通过CD40和TLR9协同激活巨噬细胞可产生不依赖T细胞的抗肿瘤作用。
J Immunol. 2006 Jan 1;176(1):309-18. doi: 10.4049/jimmunol.176.1.309.
10
Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.基于自然杀伤细胞受体及其配体的多价蛋白设计作为癌症的免疫疗法。
Expert Opin Biol Ther. 2016 Sep;16(9):1105-12. doi: 10.1080/14712598.2016.1195364. Epub 2016 Jun 9.
引用本文的文献
1
Genetic evidence from Mendelian randomization links CD40 levels to increased risk of estrogen receptor-positive breast cancer.孟德尔随机化研究的遗传证据表明，CD40水平与雌激素受体阳性乳腺癌风险增加有关。
Sci Rep. 2025 Apr 28;15(1):14892. doi: 10.1038/s41598-025-99410-0.
2
Macrophage-Based Therapeutic Strategies in Hematologic Malignancies.血液系统恶性肿瘤中基于巨噬细胞的治疗策略
Cancers (Basel). 2023 Jul 22;15(14):3722. doi: 10.3390/cancers15143722.
3
Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.肿瘤内免疫疗法治疗小鼠嗜铬细胞瘤的疗效无年龄依赖性差异。
Front Endocrinol (Lausanne). 2023 May 8;14:1030412. doi: 10.3389/fendo.2023.1030412. eCollection 2023.
4
Gestationally dependent immune organization at the maternal-fetal interface.妊娠相关的母胎界面免疫组织。
Cell Rep. 2022 Nov 15;41(7):111651. doi: 10.1016/j.celrep.2022.111651.
5
Apigenin Targets MicroRNA-155, Enhances SHIP-1 Expression, and Augments Anti-Tumor Responses in Pancreatic Cancer.芹菜素靶向微小RNA-155，增强SHIP-1表达，并增强胰腺癌的抗肿瘤反应。
Cancers (Basel). 2022 Jul 25;14(15):3613. doi: 10.3390/cancers14153613.
6
Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function.回到未来：NK 细胞抗肿瘤功能的时空决定因素。
Front Immunol. 2022 Jan 10;12:816658. doi: 10.3389/fimmu.2021.816658. eCollection 2021.
7
Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy.在基于甘露聚糖 - BAM、TLR配体和抗CD40抗体的联合免疫治疗过程中对小鼠嗜铬细胞瘤免疫细胞浸润的鉴定
Cancers (Basel). 2021 Aug 5;13(16):3942. doi: 10.3390/cancers13163942.
8
The Role of Macrophages in Cancer Development and Therapy.巨噬细胞在癌症发展与治疗中的作用
Cancers (Basel). 2021 Apr 18;13(8):1946. doi: 10.3390/cancers13081946.
9
Agonistic CD40 Antibodies in Cancer Treatment.癌症治疗中的激动性CD40抗体。
Cancers (Basel). 2021 Mar 15;13(6):1302. doi: 10.3390/cancers13061302.
10
"Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.“重教育”肿瘤相关巨噬细胞作为神经母细胞瘤的一种新型免疫治疗策略。
Front Immunol. 2020 Sep 2;11:1947. doi: 10.3389/fimmu.2020.01947. eCollection 2020.
本文引用的文献
1
Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.激动型 CD40 抗体通过抑制性 Fcγ 受体结合发挥佐剂和抗肿瘤活性。
Science. 2011 Aug 19;333(6045):1030-4. doi: 10.1126/science.1206954.
2
CD40-mediated cell death requires TRAF6 recruitment.CD40 介导的细胞死亡需要 TRAF6 的募集。
Immunobiology. 2012 Mar;217(3):375-83. doi: 10.1016/j.imbio.2011.07.007. Epub 2011 Jul 12.
3
Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.过继转移肿瘤反应性 B 细胞可赋予宿主 T 细胞免疫和肿瘤消退。
Clin Cancer Res. 2011 Aug 1;17(15):4987-95. doi: 10.1158/1078-0432.CCR-11-0207. Epub 2011 Jun 20.
4
Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.抗 CD40 单克隆抗体 dacetuzumab 和利妥昔单抗具有独特的凋亡信号特征，可增强非霍奇金淋巴瘤的抗肿瘤活性。
Clin Cancer Res. 2011 Jul 15;17(14):4672-81. doi: 10.1158/1078-0432.CCR-11-0479. Epub 2011 May 24.
5
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.CD40 激动剂可改变肿瘤基质，并在小鼠和人类中显示出对胰腺癌的疗效。
Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.
6
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.CD40 通路激活状态可预测弥漫性大 B 细胞淋巴瘤对 CD40 治疗的反应。
Sci Transl Med. 2011 Mar 16;3(74):74ra22. doi: 10.1126/scitranslmed.3001620.
7
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.辅助联合和抗原靶向作为诱导针对低免疫原性肿瘤的多功能和高亲和力 T 细胞反应的策略。
Cancer Res. 2011 May 1;71(9):3214-24. doi: 10.1158/0008-5472.CAN-10-3259. Epub 2011 Mar 14.
8
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.通过缓慢释放和局部递送激动型 CD40 抗体实现 CD8 T 细胞的局部激活和全身肿瘤消除而无毒性。
Clin Cancer Res. 2011 Apr 15;17(8):2270-80. doi: 10.1158/1078-0432.CCR-10-2888. Epub 2011 Mar 9.
9
Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.环磷酰胺联合抗 CD40 mAb 和 CpG 在小鼠中增强 T 细胞非依赖性抗肿瘤作用。
J Immunother. 2011 Jan;34(1):76-84. doi: 10.1097/CJI.0b013e318200b28a.
10
Biology and clinical applications of CD40 in cancer treatment.CD40 在癌症治疗中的生物学和临床应用。
Semin Oncol. 2010 Oct;37(5):517-23. doi: 10.1053/j.seminoncol.2010.09.002.
Zotero 插件